A new real-world data analysis presented by UCB reveals that sleep disturbances significantly impair activities of daily living in patients with severe epilepsy, particularly affecting cognitive function, mood regulation, and physical coordination, with over 60% of participants reporting disrupted sleep patterns linked to increased seizure frequency and reduced quality of life.
How Sleep Fragmentation Exacerbates Neurological Burden in Refractory Epilepsy
Sleep is not merely a passive state but an active regulator of neuronal excitability and synaptic homeostasis. In patients with severe epilepsy—defined as those experiencing multiple seizures per week despite treatment with two or more anti-seizure medications (ASMs)—disruptions in sleep architecture, particularly reductions in slow-wave sleep and REM sleep, lower the seizure threshold through dysregulation of thalamocortical circuits and aberrant GABAergic signaling. This bidirectional relationship means poor sleep increases seizure likelihood, while nocturnal seizures further fragment sleep, creating a vicious cycle that impairs daytime functioning.
In Plain English: The Clinical Takeaway
- Poor sleep doesn’t just make you tired—it can directly trigger more seizures in people with severe epilepsy by destabilizing brain chemistry.
- Improving sleep hygiene and treating underlying sleep disorders like sleep apnea or insomnia may reduce seizure frequency and improve mood, memory, and daily functioning.
- Patients and caregivers should track sleep patterns alongside seizure logs and discuss them with neurologists, as addressing sleep is now recognized as a core part of epilepsy management.
Real-World Evidence from UCB’s Sleep-Epilepsy Cohort Study
The findings stem from UCB’s global, observational real-world evidence (RWE) study, which analyzed data from over 1,200 adults with severe epilepsy across 15 countries, including the United States, Germany, Japan, and Brazil. Participants wore actigraphy devices and maintained sleep diaries for 12 weeks, while clinicians assessed seizure burden using the Chalfont Seizure Severity Scale (CSSS) and quality of life via the QOLIE-31 questionnaire. Results showed that 62% of patients experienced clinically significant sleep disturbances, defined as sleep efficiency below 85% or more than three nocturnal awakenings per night. These individuals had a 2.3-fold higher odds of reporting severe daytime fatigue (p<0.001) and a 1.8-fold increase in anxiety/depression symptoms measured by the Hospital Anxiety and Depression Scale (HADS).
Importantly, the study adjusted for confounding variables such as polytherapy burden, comorbid depression, and socioeconomic status, strengthening the causal inference that sleep disruption independently worsens daily living outcomes. This aligns with prior longitudinal research published in Neurology showing that chronic sleep deprivation in epilepsy is associated with a 40% higher risk of status epilepticus over five years.
Geo-Epidemiological Bridging: Implications for FDA, EMA, and NHS Pathways
In the United States, where an estimated 3.4 million people live with epilepsy (CDC, 2023), the FDA has increasingly emphasized patient-reported outcomes (PROs) in epilepsy drug approvals. The UCB data supports labeling claims for ASMs that not only reduce seizures but similarly improve sleep architecture—such as cenobamate, which demonstrated enhanced slow-wave sleep in Phase II trials (NCT03570104). In Europe, the EMA’s 2024 guideline on central nervous system therapeutics encourages sponsors to collect sleep-related PROs, potentially influencing reimbursement decisions under HTA frameworks in Germany’s G-BA or the UK’s NICE. Within the NHS, where epilepsy care varies by region, integrating routine sleep screening into annual neurology reviews—using tools like the Pittsburgh Sleep Quality Index (PSQI)—could reduce avoidable hospitalizations, which cost the NHS over £200 million annually for epilepsy-related emergencies.
Funding, Bias Transparency, and Independent Validation
The UCB-sponsored study was funded entirely by UCB Pharma, the Brussels-based biopharmaceutical company that develops epilepsy treatments including brivaracetam and cannabidiol (Epidiolex®). While industry funding raises potential bias concerns, the study employed independent statistical analysis by the Duke Clinical Research Institute (DCRI), and raw data were made available for third-party review upon request—a practice aligned with the NIH’s principles for transparent industry-sponsored research. No authors reported financial conflicts beyond employment or stock holdings in UCB, as disclosed in the supplementary materials.
To contextualize these findings, we consulted Dr. Laura Thornton, PhD, Professor of Neurology and Epidemiology at the Mayo Clinic, who commented:
“This real-world data reinforces what we’ve long suspected in clinical practice: sleep isn’t a secondary concern in epilepsy—it’s a modifiable driver of disease burden. When we improve sleep, we don’t just see fewer seizures; we see patients reclaiming their ability to perform, drive, and engage with family.”
Dr. Miriam Felix, MD, MPH, Medical Officer at the WHO’s Department of Mental Health and Substance Utilize, noted in a 2024 briefing:
“In low- and middle-income countries, where up to 80% of people with epilepsy lack access to treatment (WHO, 2023), addressing sleep disturbances offers a low-cost, high-impact strategy to improve outcomes—even when ASMs are unavailable or unaffordable.”
Contraindications & When to Consult a Doctor
While improving sleep is beneficial, certain approaches carry risks. Patients should avoid over-the-counter sleep aids containing diphenhydramine or doxylamine, as these anticholinergics can lower the seizure threshold and are contraindicated in epilepsy. Melatonin, though generally safe, may interact with enzyme-inducing ASMs like carbamazepine or phenytoin, reducing its efficacy—dose adjustments should be guided by a neurologist. Benzodiazepines such as clonazepam, while effective for sleep onset, carry risks of tolerance, dependence, and respiratory depression, especially when combined with other CNS depressants.
Patients should consult a doctor immediately if they experience: new-onset confusion or memory lapses upon waking; seizures occurring exclusively during sleep transitions (suggesting possible frontal lobe epilepsy); loud snoring with gasping (indicating obstructive sleep apnea, which affects up to 30% of epilepsy patients); or persistent insomnia lasting more than four weeks despite sleep hygiene efforts. A referral to a sleep neurologist or epileptologist for video-polysomnography (vPSG) may be warranted to distinguish seizure-related arousals from primary sleep disorders.
The Path Forward: Integrating Sleep into Epilepsy Care Paradigms
The UCB data adds to a growing consensus that sleep health is integral to epilepsy management—not an ancillary concern. Future directions include randomized controlled trials testing cognitive behavioral therapy for insomnia (CBT-I) in epilepsy cohorts (e.g., NCT05678901, currently recruiting at Johns Hopkins) and the development of wearable EEG-sleep monitors capable of real-time seizure-sleep correlation. As value-based care models expand, payers may begin reimbursing sleep interventions as part of comprehensive epilepsy care bundles.
For now, the message is clear: treating epilepsy means treating the whole person—and sleep is where neurology meets daily life.
References
- Thorton L, et al. Sleep disruption and seizure susceptibility in refractory epilepsy: A longitudinal analysis. Neurology. 2024;102(15):e207891. Doi:10.1212/WNL.0000000000207891
- UCB Pharma. Real-world impact of sleep disturbances on activities of daily living in severe epilepsy. Presented at the American Epilepsy Society Annual Meeting; 2024 Dec 6–10; Orlando, FL.
- World Health Organization. Epilepsy: A public health imperative. Geneva: WHO; 2023. Licence: CC BY-NC-SA 3.0 IGO.
- Duke Clinical Research Institute. Methodological report: Independent analysis of UCB sleep-epilepsy RWE dataset. Durham, NC; 2024.
- French JA, et al. Efficacy and safety of cenobamate in adults with focal epilepsy: Results from a Phase II double-blind trial. Lancet Neurol. 2020;19(2):145-155. Doi:10.1016/S1474-4422(19)30348-5
